MULTIPLE MYELOMA

The first patient recieved the novel investigational molecular glue degrader cemsidomide plus elranatamab for multiple myeloma.

Paul G. Richardson, MD, detailed the strategic integration of mezigdomide into several areas including the unmet need of post CAR T-cell therapy.

Paul G. Richardson, MD, explains the distinct potential roles and combinations including iberdomide and mezigdomide in multiple myeloma treatment.

Luciano Costa, MD, PhD, discusses the considerations for managing infection risk with bispecific antibodies in multiple myeloma.

FDA clears teclistamab plus daratumumab for early-relapse multiple myeloma, delivering striking PFS gains and scalable outpatient use.

Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy.

A single-arm study of a BCMA CAR T-cell therapy after induction for newly diagnosed multiple myeloma led to 100% minimal residual disease negativity at 3 months.

During a live event, Shaji Kumar, MD, discussed dose deescalation as a strategy for managing adverse events with talquetamab in multiple myeloma.

A real-world analysis of patients receiving teclistamab prior to 2022 showed comparable outcomes to clinical trials and indicated adoption of proactive adverse event management.

Luciano Costa, MD, PhD, discussed why the lack of high-grade cytokine release syndrome in the MajesTEC-3 trial should encourage the use of teclistamab.

In an interview, Paul G. Richardson, MD, gave an overview of the ways that CELMoDs are poised to impact the landscape of multiple myeloma treatment at various stages of disease treatment.

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

Luciano Costa, MD, PhD, discusses the how the MajesTEC-3 trial's 83% improvement in PFS contributed to a 3-month turnaround to FDA approval.

Sagar Lonial, MD, discusses the expanding potential uses of cereblon E3 ligase modulators (CELMoDs) in combination with T-cell redirection therapies in multiple myeloma.

In this interview, Sagar Lonial, MD, discusses the EXCALIBER-RRMM trial design and the potential role of iberdomide in the evolving therapeutic landscape of multiple myeloma.

Paul G. Richardson, MD, discusses the SUCCESSOR-2 trial of mezigdomide, carfilzomib, and dexamethasone in multiple myeloma.

The addition of the CELMoD mezigdomide to carfilzomib and dexamethasone led to progression-free survival improvement in relapsed/refractory multiple myeloma.

During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma.

The FDA granted approval of the combination of teclistamab and daratumumab for patients with 1-3 prior lines of therapy in myeloma.

Sagar Lonial, MD, discusses the significance of the MRD end point for the ongoing priority review of iberdomide in multiple myeloma.

Sagar Lonial, MD, discusses the evolving role of cereblon E3 ligase modulators (CELMoDs) in the treatment of multiple myeloma.

Rahul Banerjee, MD, discusses the rationale for potential therapeutic strategies to address T-cell exhaustion following CAR T-cell therapy in multiple myeloma.

During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines.

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for FDA approvals in multiple myeloma.

During a live event, Joshua Richter, MD, discussed dosing strategies when using selinexor in relapsed/refractory multiple myeloma.